{"title":"替诺福韦与恩替卡韦治疗慢性乙型肝炎的meta分析","authors":"Jian-Xing Luo , Guo Chen , Xiao-Yu Hu , Chang Yu","doi":"10.1016/j.gastre.2025.502276","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The superiority between TAF and ETV remains unclear. Which is the best choice for patients with CHB? Thus, this meta-analysis aimed to evaluate the efficacy and safety of TAF and ETV for patients with CHB.</div></div><div><h3>Methods</h3><div>MEDLINE/PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were searched for eligible studies from inception to January 2024 and a meta-analysis was done.</div></div><div><h3>Results</h3><div>24 trials with a total of 6753 subjects were screened. TAF significantly improved 12- and 24-week complete virological response (CVR), 12-week biochemical response (BR) and 24-week HBeAg loss, but could not improve 48- and 96-week CVR, 24-, 48- and 96-week BR, 96-week HBeAg loss, adverse events, 48-week HBsAg decline and loss, 12-, 24- and 48-week HBeAg seroconversion, 96-week HCC incidence compared to ETV. Subgroup analysis was conducted according to race, research type and switching. Different results were obtained from different subgroups.</div></div><div><h3>Conclusions</h3><div>TAF was superior to ETV at 12- and 24-week CVR, 12-week BR and 24-week HBeAg loss. Race and switching might affect the efficacy of TAF and ETV.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 4","pages":"Article 502276"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis\",\"authors\":\"Jian-Xing Luo , Guo Chen , Xiao-Yu Hu , Chang Yu\",\"doi\":\"10.1016/j.gastre.2025.502276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The superiority between TAF and ETV remains unclear. Which is the best choice for patients with CHB? Thus, this meta-analysis aimed to evaluate the efficacy and safety of TAF and ETV for patients with CHB.</div></div><div><h3>Methods</h3><div>MEDLINE/PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were searched for eligible studies from inception to January 2024 and a meta-analysis was done.</div></div><div><h3>Results</h3><div>24 trials with a total of 6753 subjects were screened. TAF significantly improved 12- and 24-week complete virological response (CVR), 12-week biochemical response (BR) and 24-week HBeAg loss, but could not improve 48- and 96-week CVR, 24-, 48- and 96-week BR, 96-week HBeAg loss, adverse events, 48-week HBsAg decline and loss, 12-, 24- and 48-week HBeAg seroconversion, 96-week HCC incidence compared to ETV. Subgroup analysis was conducted according to race, research type and switching. Different results were obtained from different subgroups.</div></div><div><h3>Conclusions</h3><div>TAF was superior to ETV at 12- and 24-week CVR, 12-week BR and 24-week HBeAg loss. Race and switching might affect the efficacy of TAF and ETV.</div></div>\",\"PeriodicalId\":100569,\"journal\":{\"name\":\"Gastroenterología y Hepatología (English Edition)\",\"volume\":\"48 4\",\"pages\":\"Article 502276\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterología y Hepatología (English Edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2444382425000264\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterología y Hepatología (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444382425000264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景 TAF 和 ETV 之间的优劣仍不明确。对于慢性乙型肝炎患者来说，哪种药物是最佳选择？MEDLINE/PubMed、Cochrane Library、EMBASE、Web of Science和CNKI检索了从开始到2024年1月符合条件的研究，并进行了荟萃分析。与ETV相比，TAF能明显改善12周和24周完全病毒学应答（CVR）、12周生化应答（BR）和24周HBeAg丢失，但不能改善48周和96周CVR、24周、48周和96周BR、96周HBeAg丢失、不良事件、48周HBsAg下降和丢失、12周、24周和48周HBeAg血清转换、96周HCC发生率。根据种族、研究类型和转换进行了亚组分析。结论TAF在12周和24周CVR、12周BR和24周HBeAg丢失方面均优于ETV。种族和转换可能会影响 TAF 和 ETV 的疗效。
Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis
Background
The superiority between TAF and ETV remains unclear. Which is the best choice for patients with CHB? Thus, this meta-analysis aimed to evaluate the efficacy and safety of TAF and ETV for patients with CHB.
Methods
MEDLINE/PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were searched for eligible studies from inception to January 2024 and a meta-analysis was done.
Results
24 trials with a total of 6753 subjects were screened. TAF significantly improved 12- and 24-week complete virological response (CVR), 12-week biochemical response (BR) and 24-week HBeAg loss, but could not improve 48- and 96-week CVR, 24-, 48- and 96-week BR, 96-week HBeAg loss, adverse events, 48-week HBsAg decline and loss, 12-, 24- and 48-week HBeAg seroconversion, 96-week HCC incidence compared to ETV. Subgroup analysis was conducted according to race, research type and switching. Different results were obtained from different subgroups.
Conclusions
TAF was superior to ETV at 12- and 24-week CVR, 12-week BR and 24-week HBeAg loss. Race and switching might affect the efficacy of TAF and ETV.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
